HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Bezafibrate

Subscribe to New Research on Bezafibrate

An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.

Also Known As:

Azufibrat; Azupharma Brand of Bezafibrate; BM-15.075; Bayer Brand of Bezafibrate; Befibrat; Berlin-Chemie Brand of Bezafibrate; Betapharm Brand of Bezafibrate; Beza-Lande; Beza-Puren; Bezabeta; Bezacur; Bezafibrat PB; Bezafisal; Bezalip; Bezamerck; Boehringer Mannheim Brand of Bezafibrate; Béfizal; Cedur; Cryopharma Brand of Bezafibrate; Difaterol; Elfar Brand of Bezafibrate; Eulitop; Hennig Brand of Bezafibrate; Hexal Brand of Bezafibrate; Isis Brand of Bezafibrate; Lakeside Brand of Bezafibrate; Lipox; Merckle Brand of Bezafibrate; Reducterol; Regadrin B; Roche Brand of Bezafibrate; Sklerofibrat; Solibay; Synthelabo Brand of Bezafibrate; TAD Brand of Bezafibrate; Teva Brand of Bezafibrate; durabezur; BM 15.075; BM15.075; Berlin Chemie Brand of Bezafibrate; Beza Lande; Beza Puren; BezaLande; BezaPuren; Bezafibrate Azupharma Brand; Bezafibrate Bayer Brand; Bezafibrate Berlin-Chemie Brand; Bezafibrate Betapharm Brand; Bezafibrate Cryopharma Brand; Bezafibrate Elfar Brand; Bezafibrate Hennig Brand; Bezafibrate Hexal Brand; Bezafibrate Isis Brand; Bezafibrate Lakeside Brand; Bezafibrate Merckle Brand; Bezafibrate Roche Brand; Bezafibrate Synthelabo Brand; Bezafibrate TAD Brand; Bezafibrate Teva Brand; PB, Bezafibrat; Propanoic acid, 2-(4-(2-((4-chlorobenzoyl)amino)ethyl)phenoxy)-2-methyl-

Networked: 527 relevant articles (72 outcomes, 181 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Boyko, Valentina: 30 articles (12/2010 - 01/2002)
2.	Behar, Solomon: 27 articles (03/2009 - 01/2002)
3.	Tenenbaum, Alexander: 21 articles (01/2014 - 05/2002)
4.	Fisman, Enrique Z: 19 articles (01/2014 - 05/2002)
5.	Tanne, David: 19 articles (03/2009 - 01/2002)
6.	Goldbourt, Uri: 18 articles (02/2013 - 01/2002)
7.	Goldenberg, Ilan: 13 articles (01/2014 - 10/2003)
8.	Adler, Yehuda: 13 articles (01/2009 - 01/2002)
9.	Haim, Moti: 12 articles (02/2013 - 01/2002)
10.	Benderly, Michal: 12 articles (02/2013 - 01/2006)

Related Diseases

1.	Hyperlipidemias (Hyperlipidemia) 01/01/1998 - "This unique characteristic of bezafibrate, which possesses both a hypolipidemic effect and antioxidant activity, may be beneficial in preventing vascular complications in hyperlipidemia." 09/01/1988 - "These results suggest that bezafibrate is effective in the treatment of hyperlipidemia." 04/16/2000 - "First line treatment with bezafibrate, or statins in some with combined hyperlipidemia, had failed. " 05/01/2010 - "Bezafibrate retard is a commonly used medication for hyperlipidemia. " 11/01/2000 - "Bezafibrate is naturally used for hyperlipidemia worldwide. "
2.	Biliary Liver Cirrhosis (Primary Biliary Cirrhosis) 02/01/2005 - "The therapeutic efficacy of bezafibrate, a hypolipidemic drug, has been shown in patients with primary biliary cirrhosis (PBC) in some pilot studies; however, little is known regarding the mechanism of action of bezafibrate in PBC. " 02/01/2005 - "Therapeutic efficacy of decreased nitrite production by bezafibrate in patients with primary biliary cirrhosis." 04/01/2002 - "Is bezafibrate histologically effective for primary biliary cirrhosis?" 01/01/2002 - "Investigation into the efficacy of bezafibrate against primary biliary cirrhosis, with histological references from cases receiving long term monotherapy." 01/01/2012 - "We need more randomised clinical trials on the effects of bezafibrate on primary biliary cirrhosis with low risks of systematic errors and random errors."
3.	Dyslipidemias (Dyslipidemia) 01/01/2012 - "In clinical trials bezafibrate was highly effective for cardiovascular risk reduction in patients with metabolic syndrome and atherogenic dyslipidemia. " 01/01/2010 - "Bezafibrate may be effective for ovulation induction in CC-resistant PCOS patients with dyslipidemia." 06/08/2005 - "Bezafibrate effectively ameliorates atherogenic dyslipidemia by reducing remnants and small LDL as well as by increasing HDL particles in hypertriglyceridemic subjects." 01/29/2008 - "Secondary prevention with bezafibrate therapy for the treatment of dyslipidemia: an extended follow-up of the BIP trial." 07/01/2013 - "Thirty-two essential hypertensive patients with dyslipidemia (6 men and 26 women, mean age 65±8 years old) were assigned to a control period and a bezafibrate period (200 mg twice daily) for 8 weeks each in a randomized crossover manner. "
4.	Hyperlipoproteinemias 12/06/1980 - "[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]." 06/29/1985 - "These findings show that bezafibrate affords safe and effective long-term treatment of patients with hyperlipoproteinemia." 01/01/1990 - "Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia." 06/29/1985 - "Bezafibrate, a new hypolipidemic agent, was evaluated in a single blind, placebo-controlled study lasting 14 months to 3 years in 40 patients with primary hyperlipoproteinemia of various types (23 patients with type II, 15 with type IV and 2 with type V). " 01/01/1992 - "The efficacy and safety of bezafibrate were evaluated in 83 patients with type IIa, IIb, or IV hyperlipoproteinemia. "
5.	Inflammation 11/01/2011 - "Our results indicate that bezafibrate is superior to omega-3 fatty acid in inhibiting systemic inflammation and lymphocyte secretory function." 10/01/2008 - "Bezafibrate improved hepatic steatosis and potently prevented inflammation, oxidative stress, HSC activation, and fibrogenesis in the liver. " 06/08/2005 - "None of inflammation makers showed significant change by bezafibrate. " 04/01/2003 - "Our results suggest that bezafibrate reduces hyperlipidemia, inhibits pancreatic inflammation, and prevents pancreatic degeneration in obese and diabetic OLETF rats." 07/01/2011 - "Our study suggests that bezafibrate is superior to omega-3 fatty acids in reducing systemic inflammation and in producing monocyte-suppressing effects. "

Related Drugs and Biologics

1.	Ursodeoxycholic Acid (Urso)
2.	Insulin (Novolin)
3.	Gemfibrozil (Lopid)
4.	Triglycerides (Triacylglycerol)
5.	Lipoproteins (Lipoprotein)
6.	Fibric Acids (Fibrates)
7.	Glucose (Dextrose)
8.	PPAR alpha
9.	Enzymes
10.	Lovastatin (Mevacor)

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Highly Active Antiretroviral Therapy (HAART)
3.	Hematopoietic Stem Cell Transplantation
4.	Heart Transplantation (Grafting, Heart)
5.	Plasma Exchange